TNF and rheumatoid arthritis: found that treatment persistence in patients with RA was longest in those receiving anti-TNF therapy in combination with a csDMARD, with approximately 50% of patients remaining on treatment for 270 days, compared with approximately 30% of those on anti-TNF therapy alone [13].